• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

    3.140 -3.280 (-51.09%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Fulcrum Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Keep an eye on the top gainers and losers in Tuesday's session. ↗
    Via Chartmill
    These stocks are moving in today's session ↗
    Via Chartmill
    Tuesday's session: gap up and gap down stocks ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    Fulcrum Therapeutics (NASDAQ:FULC) Beats Q1 Estimates as Pociredir Data Fuels Optimism ↗
    Via Chartmill
    Fulcrum Therapeutics (NASDAQ:FULC) Q4 2025 Earnings: Pociredir Data Steals Spotlight Amid In-Line Financials ↗
    Via Chartmill
    Which stocks are moving after the closing bell on Monday? ↗
    Via Chartmill
    News headline image
    Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum (FULC) Q1 2026 Earnings Transcript ↗
    Fulcrum (FULC) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
    CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular... 
    Via MarketMinute
    News headline image
    Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
    CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years.... 
    Via MarketMinute
    News headline image
    MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
    Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis 
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active
    Via AB Newswire
    News headline image
    Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    What's going on in today's session ↗
    Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
    Via Chartmill
    News headline image
    There are notable gap-ups and gap-downs in today's session. ↗
    There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
    Via Chartmill
    News headline image
    Wondering what's happening in today's pre-market session? ↗
    Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
    Via Chartmill
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.